Advertisement

Topics

MedImmune Company Profile

18:17 EDT 21st September 2018 | BioPortfolio

MedImmune Incorporated is a biotechnology company headquartered in Gaithersburg, Maryland with three products on themarket and a diverse product development portfolio. MedImmune is focused on using advances in immunology and other biological sciences to develop important new products that address significant medical needs in areas such as infectious diseases, transplantation medicine, autoimmune diseases and cancer. In 1998, the Company launched Synagis (palivizumab) in the United States for preventing respiratory syncytial virus (RSV) in high-risk pediatric patients. Synagis is the first monoclonal antibody approved for an infectious disease and has become an important new pediatric product for the prevention of RSV, the leading cause of pneumonia and bronchiolitis in infants and children. The Company also markets CytoGam (Cytomegalovirus Immune Globulin Intravenous (Human), CMV-IGIV) and RespiGam (Respiratory Syncytial Virus

Immune Globulin Intravenous (Human), RSV-IGIV) and has five new product candidates undergoing clinical trials.

Location

One MedImmune Way
Gaithersburg
MD
20878
United States of America

Contact

Phone: (301) 398-0000
Fax: 301 527 4200
Email: infobusdev@medimmune.com


News Articles [87 Associated News Articles listed on BioPortfolio]

Kiniksa licenses mavrilimumab from MedImmune

MedImmune LLC granted Kiniksa Pharmaceuticals Ltd. exclusive global rights to develop and sell the granulocyte macrophage colony stimulating factor (GM-CSF) antagonist mavrilimumab. Kiniksa also gets ...

Compugen and MedImmune enter exclusive license agreement

MedImmune LLC and Compugen Ltd. penned an agreement for the development of bispecific and multi-specific antibody therapies for cancer.

Medimmune: Joining forces with Amgen to develop and commercialise clinical-stage inflammation portfolio.

In this episode of PharmaTelevision News Review, filmed at #BIO2012 Convention in Boston, Fintan Walton talks to Atul Saran, SVP Corporate Development and Ventures at Medimmune.

AstraZeneca Creates Viela Bio from MedImmune Arm

MedImmune, the biologics R&D arm of Anglo-Swedish drugmaker AstraZeneca, is spinning out six molecules from its early-stage inflammation and autoimmunity programs into new independent biotech, Vie...

MedImmune: Open, transparent and collaborative

Jane Osbourne (Vice President, Research and Development at MedImmune), discusses AstraZeneca’s recent move to Cambridge, the company’s strategy for collaboration. She also discusses her role with ...

MedImmune taps Israeli bi-specific antibody programme

MedImmune will make bi-specific and multi-specific antibody products developed from Compugenâs pipeline under an exclusive license agreement.

MedImmune launches Digital Health Challenge in the UK

Start ups and entrepreneurs in the UK who have developed, or are looking to create, a digital healthcare solution are being invited to submit entries to a new prize fund organised by MedImmune. The w...

MedImmune, Compugen sign immuno-oncology deal

Compugen has signed an exclusive license agreement with AstraZeneca’s subsidiary MedImmune for the development of bi-specific and multi-specific immuno-oncology antibody products.

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.

Intranasally administered live attenuated influenza vaccine (LAIV) was initially licensed in the United States in 2003 as a trivalent formulation (LAIV3) (FluMist, MedImmune, LLC). Quadrivalent live a...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

The goals of this study are to describe the safety, reactogenicity and immunogenicity of MEDI-517 with and without adjuvant in HPV-naïve humans. Long-term immune data is collected. This ...

Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women

The purpose of this phase IIB MedImmune-sponsored study was to evaluate the efficacy of the HPV-16/18 VLP vaccine in the prevention of infection with HPV-16 and/or HPV-18 in adolescent and...

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

The purpose of this Phase II study is to provide data regarding the safety and immunogenicity for a range of dose levels of MEDI-517 in women who are HPV-16/18 seronegative and negative fo...

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Human Papilloma viruses (HPV) are viruses that cause infections of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, ...

Durvalumab in Pediatric and Adolescent Patients

Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G1 kappa subclass that inhibits binding of Programmed Death Ligand 1 (PD-L1) and is being developed by AstraZeneca/Med...

Companies [17 Associated Companies listed on BioPortfolio]

RollStream and MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland...

MedImmune

MedImmune Incorporated is a biotechnology company headquartered in Gaithersburg, Maryland with three products on themarket and a diverse product development portfolio. MedImmune is focused on using a...

ADC Therapeutics Sarl

ADC Therapeutics (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cance...

Applied Genetic Technologies, Corporation,

Applied Genetic Technologies Corporation (AGTC) was founded in January, 1999 by five scientific leaders in the use of viral vectors for Gene Therapy. They subsequently secured rights to a portfolio of...

Genaera Corporation

Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma.

More Information about "MedImmune" on BioPortfolio

We have published hundreds of MedImmune news stories on BioPortfolio along with dozens of MedImmune Clinical Trials and PubMed Articles about MedImmune for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MedImmune Companies in our database. You can also find out about relevant MedImmune Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record